NEO stock news · NeoGenomics, Inc.

Stories about NeoGenomics, Inc. (NEO) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for NEO

Follow NeoGenomics, Inc. (NEO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Free on the App Store and Google Play, or on the web.

Oct 30, 2026, 6:07 PM ET · Opinion
TD Cowen says NeoGenomics is still a good buy and has raised its price target to $23.
Good for NEO
TD Cowen kept its Buy rating on NeoGenomics and raised its share target to $23 per share from $19 per share. This is a positive sign from one analyst, not new proof of business growth.
Oct 6, 2026, 1:57 PM ET · Market
Why is NeoGenomics stock dropping on Tuesday?
Neutral
NeoGenomics reported 28% growth in next-generation sequencing testing, but still expects a loss and kept its 2026 sales forecast unchanged. The update does not clearly change its outlook.